VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages

Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic, with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being affected the most. In this work, we asked whether two previously identified human cross-neutralizing nAbs, iB14 (class VH1-58)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulemzin, Sergey V., Sergeeva, Maria V., Baranov, Konstantin O., Gorchakov, Andrey A., Guselnikov, Sergey V., Belovezhets, Tatyana N., Volkova, Olga Yu., Najakshin, Alexander M., Chikaev, Nikolai A., Danilenko, Daria M., Taranin, Alexander V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224930/
https://www.ncbi.nlm.nih.gov/pubmed/35743680
http://dx.doi.org/10.3390/jpm12060895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224930/
https://www.ncbi.nlm.nih.gov/pubmed/35743680
http://dx.doi.org/10.3390/jpm12060895

Ejemplares similares